Skip navigation

Strategic and Tactical Decisions for Long Term Success

January 23-24, 2019
  • Alexandria, VA

Mitigate Risk – Navigate Evolving Regulations –
Accelerate Market Access

As more biosimilar products continue to be added to the FDA pipeline, it is critical that pharmaceutical companies develop strategies to comply with evolving regulations, mitigate risk and execute long-term decisions to prepare for success. At CBI’s 14th Biosimilars Summit, you’ll gain insights from industry experts on the tools and strategies needed to prepare for the impending changes impacting all elements of the healthcare industry.

Hear insights from key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing everything from navigating impending regulations, determining optimal pricing models, accelerating market access strategies and executing strategic, long-term decisions to mitigate risk and build for success.

Join CBI’s 14th Biosimilars Summit and explore the current U.S. climate for biosimilars, evaluate competition and benchmark with industry peers on how to navigate the changing regulations and landscape of the biosimilars market and effectively bring these programs to market.

Hear Expert Insights On:

  • Critical updates on the latest FDA biosimilar guidance
  • Payer insights on leveraging interchangeability data,
    formulary placement and reimbursement
  • Biosimilar uptake and product switching policies
    across various care models
  • Stakeholder engagement and commercial potential
    through successful product marketing
  • State pharmacy law considerations and common
    differences between retail and hospital pharmacies
  • Patient experience for biosimilar drugs in EHRs to
    reduce overall cost of patient acquisition
  • HCPCS Biosimilar J-Codes impact on
    reimbursement and pricing
  • And more!

ACCLAIM FOR INDUSTRY’S MUST-ATTEND EVENT:

14th Biosimilars Summit

Strategic and Tactical Decisions for Long Term Success

Mitigate Risk – Navigate Evolving Regulations –
Accelerate Market Access

As more biosimilar products continue to be added to the FDA pipeline, it is critical that pharmaceutical companies develop strategies to comply with evolving regulations, mitigate risk and execute long-term decisions to prepare for success. At CBI’s 14th Biosimilars Summit, you’ll gain insights from industry experts on the tools and strategies needed to prepare for the impending changes impacting all elements of the healthcare industry.

Hear insights from key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing everything from navigating impending regulations, determining optimal pricing models, accelerating market access strategies and executing strategic, long-term decisions to mitigate risk and build for success.

Join CBI’s 14th Biosimilars Summit and explore the current U.S. climate for biosimilars, evaluate competition and benchmark with industry peers on how to navigate the changing regulations and landscape of the biosimilars market and effectively bring these programs to market.

Hear Expert Insights On:

  • Critical updates on the latest FDA biosimilar guidance
  • Payer insights on leveraging interchangeability data,
    formulary placement and reimbursement
  • Biosimilar uptake and product switching policies
    across various care models
  • Stakeholder engagement and commercial potential
    through successful product marketing
  • State pharmacy law considerations and common
    differences between retail and hospital pharmacies
  • Patient experience for biosimilar drugs in EHRs to
    reduce overall cost of patient acquisition
  • HCPCS Biosimilar J-Codes impact on
    reimbursement and pricing
  • And more!

ACCLAIM FOR INDUSTRY’S MUST-ATTEND EVENT: